Mechanism of Action: Selective and reversibly bound antagonist of the P2Y$_{12}$ receptor. Inhibits ADP-mediated platelet activation and aggregation.

BACKGROUND
Ticagrelor is a cyclopentyltriazolopyrimidine antiplatelet agent.

Place in Therapy
Use of ticagrelor at UHN is limited to any patient presenting with an acute coronary syndrome, with or without ST segment elevation, regardless of management strategy. (This includes patients managed invasively and those managed conservatively). Patients treated with fibrinolysis are excluded. Compared to clopidogrel, ticagrelor is considered to provide more rapid, more consistent, and more potent platelet inhibition at a cost of higher bleeding rates.

Summary of Efficacy Endpoints from PLATO:¹
In patients presenting with ACS, with or without ST segment elevation, use of ticagrelor compared with clopidogrel was associated with a significant reduction in the rate of the primary endpoint of cardiovascular death/MI/stroke and a significant reduction in overall mortality.

<table>
<thead>
<tr>
<th>End Point</th>
<th>Ticagrelor (n=9333)</th>
<th>Clopidogrel (n=9291)</th>
<th>HR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary end point, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CV death/MI/stroke</td>
<td>864 (9.8)</td>
<td>1,014 (11.7)</td>
<td>0.84 (0.77-0.92)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Secondary end points, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total death/MI/stroke</td>
<td>901 (10.2)</td>
<td>1,065 (12.3)</td>
<td>0.84 (0.77-0.92)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CV death/MI/stroke/ischaemia/TIA/arterial</td>
<td>1,290 (14.6)</td>
<td>1,456 (16.7)</td>
<td>0.88 (0.81-0.95)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>thrombotic events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>504 (5.8)</td>
<td>593 (6.9)</td>
<td>0.84 (0.75-0.95)</td>
<td>0.005</td>
</tr>
<tr>
<td>CV death</td>
<td>353 (4.0)</td>
<td>442 (5.1)</td>
<td>0.79 (0.69-0.91)</td>
<td>0.001</td>
</tr>
<tr>
<td>Stroke</td>
<td>125 (1.5)</td>
<td>106 (1.3)</td>
<td>1.17 (0.91-1.52)</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Total death</strong></td>
<td>399 (4.5)</td>
<td>506 (5.9)</td>
<td>0.78 (0.69-0.89)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Dosing: Loading Dose: 180 mg (2 x 90 mg tablets) PO once, then 90 mg PO BID

Dose Adjustments: No dosage adjustment is required in patients with renal or mild hepatic impairment. Ticagrelor is contraindicated in those with moderate to severe hepatic impairment.

Administration
• Ticagrelor can be taken without regard to food.
• If a patient has difficulty swallowing a whole tablet, the film-coated tablets may be administered by dispersing them in 200 mL water and giving the dispersion orally or via nasogastric tube.

Switching from ticagrelor to clopidogrel: Refer to Antiplatelet Therapy Switching - Clinician Guide.

PHARMACOLOGIC PROFILE AND LABORATORY MONITORING
There is no specific lab parameter which indicates the extent of antiplatelet activity.

**Onset of Platelet Aggregation Inhibition:** <30 minutes with 180 mg loading dose

**Peak Effect:** 2.5 hours

**Half-Life:** of active metabolite is approximately 8.6 hours (6.5-12.8 hours)

**Duration of Effect:** 2-3 days; platelet aggregation will return to baseline 5-7 days after discontinuation

**Bioavailability:** 36% (25.4%-64.0%)

**Elimination:** 26% urine, 58% feces

**CONTRAINDICATIONS**
- hypersensitivity to ticagrelor or any ingredient in the formulation
- patients with active bleeds or high bleeding risk (advanced age, gastric ulcer, previous bleeding)
- patients with history of intracranial hemorrhage
- patients with moderate to severe hepatic impairment
- concomitant use of strong CYP3A4 inhibitors (increased plasma concentration of ticagrelor):
  - ketoconazole, clarithromycin, ritonavir, atazanavir

**PRECAUTIONS**
- Caution in patients with bradycardia, hyperuricemia and in patients likely to have dyspnea
- **Pharmacodynamic drug interactions**
  - Concomitant use of other antiplatelet agents (e.g., ASA, clopidogrel) or other anticoagulants (warfarin, low molecular weight heparins, unfractionated heparin, fondaparinux, dabigatran) will increase the risk of bleeding.
  - During clinical studies, ticagrelor was commonly administered with ASA, heparin, low molecular weight heparin, intravenous GpIIb/IIIa inhibitors, proton pump inhibitors, statins, beta-blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers as needed for concomitant conditions, and did not produce any evidence of clinically significant drug interactions.
- **Pharmacokinetic drug interactions**
  - CYP3A4 inhibitors (increase serum concentration of ticagrelor, decrease serum concentration of active metabolite):
    - Ketoconazole, clarithromycin, ritonavir, atazanavir
  - CYP3A4 inducers (decrease serum concentration of ticagrelor):
    - Rifampin, dexamethasone, phenytoin, carbamazepine, phenobarbital
  - PGP substrates
    - Increase serum concentration of digoxin

**ADVERSE EFFECTS**
- bleeding
- dyspnea (mild-moderate, transient)
- headache
- nausea, vomiting, diarrhea
Cardiac Diseases and Therapies
ACUTE CORONARY SYNDROMES

TICAGRELOR (Brilinta®) CLINICIAN SUMMARY

• hyperuricemia

Summary of safety endpoints from PLATO
Compared to clopidogrel, use of ticagrelor was associated with significantly higher rates of:
- Non-CABG-related major bleeding
- intracranial bleeding
- fatal intracranial bleeding
There was no significant difference in the rates of major bleeding or in the rates of CABG-related major bleeding with ticagrelor.

PREPARATION FOR SURGICAL PROCEDURES INCLUDING CABG
Excess bleeding risk due to recent administration of ticagrelor in patients selected to have CABG should be weighed against the potential lost benefit of adequate platelet inhibition in early ACS. In patients who may require urgent CABG or urgent non-cardiac surgery, consider discontinuation with the knowledge that platelet function will recover in 5-7 days.

MANAGEMENT OF BLEEDING
• Due to the reversible antagonism of the P2Y_{12} receptor, recovery of platelet function is faster with ticagrelor than with irreversible P2Y_{12} receptor antagonists, such as clopidogrel or prasugrel.
• Because the drug is reversibly bound, platelet transfusion is unlikely to be effective.
• No antidote exists for reversal of antiplatelet effect.
• Ticagrelor is not expected to be dialyzable.
• May Consider:
  o transfusion of blood products
  o Haematology consult should be obtained for assistance

REFERENCES
Terms and Conditions

Copyright © University Health Network, 2014. All rights reserved.

The contents of this Handbook are approved and endorsed by the UHN Cardiovascular Subcommittee of the Pharmacy and Therapeutics Committee.

1. Purpose of the Pharmacotherapy Handbook.

Notice to Healthcare Providers:

The Pharmacotherapy Handbook is intended to be used as a tool to aid in the appropriate prescribing and administration of cardiovascular formulary agents.

This information in this Handbook is intended for use by and with experienced physicians and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about Cardiovascular illness and the treatments in question.

Due to the rapidly changing nature of cardiovascular treatments and therapies, users are advised to recheck the information contained herein with the original source before applying it to patient care.

Notice to non-Healthcare Providers:

Not Medical Advice. The information contained in the Handbook is not a substitute for professional medical advice, diagnosis or treatment. Never make changes to your medication, nor adjust your dose, without first consulting your health care provider. Always seek the advice of a physician or other qualified healthcare provider concerning questions you have regarding a medical condition, and before starting, stopping or modifying any treatment or medication. Never delay obtaining medical advice or disregard medical advice because of something you have or have not read in the Handbook. If you have, or suspect you have, a health problem, or if you experience an adverse side effect, please consult your doctor. If you have, or suspect you are experiencing a health emergency, please call 911 and/or promptly visit a Hospital Emergency Department in your area.

2. DISCLAIMER: UNIVERSITY HEALTH NETWORK MAKES NO WARRANTIES OR REPRESENTATIONS AS TO THE ACCURACY OF THE INFORMATION PROVIDED. THE INFORMATION CONTAINED IN OR PRESENTED IN THIS HANDBOOK COMES WITHOUT ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED. ANY IMPLIED WARRANTY OR CONDITION OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF NON-INFRINGEMENT OF THIRD PARTY RIGHTS, AND FREEDOM FROM COMPUTER VIRUSES, IN RESPECT OF THE HANDBOOK IS EXPRESSLY DISCLAIMED.

3. Disclaimer. Neither UHN, as an entity, nor any of its staff or contractors cannot under any circumstance be held liable for consequences caused by or deriving from the use of the Handbook or any information contained in the Handbook. UHN is not liable for damages arising from use of the Handbook, or from third party websites (via hyperlinks) to which references are made in the Handbook. In no event shall UHN be liable for direct, indirect, consequential, special, exemplary, or other damages related to your use of the Handbook, regardless of how arising or the theory of liability whether arising in contract, tort, negligence or otherwise.

Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites, including but not limited to the terms and conditions of http://pie.med.utoronto.ca/ on which this Handbook is housed.

4. Governing Law and Jurisdiction. Any action or claim arising from or related to your use of the Handbook shall be brought in the courts of, and governed exclusively by, the laws of Ontario, Canada and the applicable laws of Canada applicable therein, without regard to its conflicts of laws principles. Unless prohibited by applicable law, you expressly waive the right to participate in a class action proceeding.

Your comments on the usefulness of the resources contained in the Handbook are welcomed and may be forwarded to Amita Woods, Department of Pharmacy Services (amita.woods@uhn.ca).